Catalog No.
Product Name
Application
Product Information
Citations
-
CYP2C9 inhibitor
Benzbromarone is a CYP2C9 inhibitor, it binds to CYP2C9 with Ki value of 19.3 nM. - Chlorzoxazone is a muscle-relaxing drug,and a probe for human liver cytochrome P-450IIE1.
-
CYP1A1 inhibitor
Bergamottin is a furanocoumarin found in grapefruit juice and lemon, lime, and bergamot oils that has diverse biological activities. -
CYP51 inhibitor
Tebuconazole is a triazole fungicide used agriculturally to treat plant pathogenic fungi. -
liver CYP3A4 substrate
Pradefovir mesylate is a good substrate for liver CYP3A4. Pradefovir is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with a Km of 60 μM. -
CYP450 dependent inhibitor
Liarozole dihydrochloride (R75251; R85246) is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase). -
Cytochrome P450 hibitor
Gentiopicroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC50 and a Ki of 61 ?M and 22.8 ?M for CYP2A6; Gentiopicroside has antianti-inflammatoryand antioxidative effects. - Ticlopidine (Yuclid, Ticlopidinum, Ticlopidina) is an orally active inhibitor of platelet aggregation induced by adenosine diphosphate (ADP).
-
anti-inflammatory agent
Cepharanthine is an alkaloid derived from Stephania cepharantha Hayata, with possesses anti-inflammatory and antioxidative activities. -
CYP3A4 inducer
RO6889678 is an inhibitor of HBV with a complex ADME profile. RO6889678 showed an intracellular enrichment of 78-fold in hepatocytes, with an apparent intrinsic clearance of 5.2 ?l/min per mg protein and uptake and biliary clearances of 2.6 and 1.6 ?l/min per mg protein, respectively. -
Cholesterol 24-hydroxylase (CH24H) inhibitor
Soticlestat, also known as TAK 935 and OV935, is an inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). -
CYP51 inhibitor
Oteseconazole (VT-1161) is an orally active anti-fungal agent, potently binds to and inhibits Candida albicans CYP51 (Kd, <39 nM), shows no obvious effect on human CYP51. -
DAF-9 cytochrome P450 inhibitor
Dafadine-A, an analog of dafadine, is a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans; also inhibits the mammalian ortholog of DAF-9(CYP27A1). -
CYP17 lyase inhibitor
Seviteronel (VT-464) is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition. -
CYP26 inhibitor/RAMBA
Talarozole (R115866) is an oral systemic all-trans retinoic acid metabolism blocking agent (RAMBA) which increases intracellular levels of endogenous all-trans retinoic acid (RA). Talarozole inhibits both CYP26A1 and CYP26B1 with IC50s of 5.4 and 0.46 nM, respectively. -
peptidoleukotrienes antagonist
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 ?M. -
cytochrome P450 1B1 inhibitor
1-Ethynylnaphthalene is a selective inhibitor of cytochrome P450 1B1. -
EMT inhibitor
EMT inhibitor-2 inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively. -
fungal Cyp51 inhibitor
Quilseconazole (VT-1129) is a potent, orally active fungal Cyp51 (lanosterol 14-α-demethylase) inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes. - Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR).
-
Cytochrome P450 inhibitor
4'-Methylchrysoeriol is a potent inhibitor of Cytochrome P450 enzymes, with an IC50 of 19 nM for human P450 1B1-dependent EROD. -
CYP3A4 Inhibitor
Azithromycin, derived from erythromycin, is a antibiotic. Azithromycin binds to the 50S subunit of the bacterial ribosome, and thus inhibits translation of mRNA. -
CYP2C19/CYP2B6 inhibitor
Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. -
FGFR/CYP Inhibitor
FGFR-IN-10 is an orally bioactive inhibitor targeting fibroblast growth factor receptors (FGFR) and various cytochrome P450 enzymes (CYPs). It demonstrates significant potency against both wild type and V564F mutant FGFR2, with IC50 values of 104.1 nM and 43.6 nM, respectively. Additionally, FGFR-IN-10 inhibits CYP enzymes, including CYP2C9 (IC50: 3.33 µM), CYP2C19 (IC50: 18.75 µM), CYP2D6 (IC50: 4.34 µM), and CYP3A4 (IC50: 0.69 µM). This compound is valuable for researching FGFR-related signaling pathways and the pharmacokinetics of drug metabolism. -
CYP2C9/CYP3A4 Inhibitor
Tetrahydrocurcumin-d6 is a deuterated analog of Tetrahydrocurcumin, functioning as an inhibitor of CYP2C9 and CYP3A4 enzymes. This compound exhibits significant biological activity against these cytochrome P450 isoforms, making it valuable for research into drug metabolism and pharmacokinetics. Tetrahydrocurcumin-d6 is utilized in studies aiming to elucidate the metabolic pathways and interactions of curcuminoids, as well as their potential therapeutic applications. -
CYP2C8 Inhibitor
Gemfibrozil 1-O-β-glucuronide is a competitive inhibitor of the CYP2C8 enzyme, exhibiting an IC50 of 4.07 μM. As a metabolite of Gemfibrozil, this compound plays a significant role in studying drug metabolism and interactions, particularly within the context of lipid metabolism and therapeutic drug monitoring. Its inhibition capacity makes it relevant for research focused on pharmacokinetics and the effects of CYP2C8 modulation on drug efficacy and safety. -
CYP2E1 Inhibitor
CYP2E1-IN-1 is a potent inhibitor of cytochrome P450 2E1 (CYP2E1) with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM. This compound activates the Nrf2/HO-1 signaling pathway and effectively inhibits reactive oxygen species (ROS) production, contributing to the alleviation of pancreatic injury. With significant anti-inflammatory and antioxidant properties, CYP2E1-IN-1 is suitable for research applications focused on severe acute pancreatitis and other inflammation-related diseases. -
CYP1A Inducer
β-Apo-8'-carotenal is a potent inducer of CYP1A, acting through the aryl hydrocarbon receptor (AhR) pathway. This carotenoid has demonstrated the ability to induce DNA strand breaks and lipid peroxidation in cancer cells, making it a valuable tool for research into cancer biology and metabolic disorders. Its role as a provitamin A compound further emphasizes its potential applications in studies related to cellular metabolism and disease mechanisms. -
CYP51 Inhibitor
Antifungal agent 136 is an irreversible inhibitor of fungal lanosterol 14α-demethylase (CYP51). It demonstrates potent antifungal activity against drug-resistant strains of Candida albicans and effectively downregulates IL-6 expression. This compound holds potential for research applications in the fields of fungal infection and inflammatory diseases. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
CYP2C19 Inhibitor
CYP2C19-IN-1 is a selective inhibitor of the cytochrome P450 enzyme CYP2C19, exhibiting a favorable safety profile with no hepatotoxicity or Ames test toxicity. It demonstrates potent inhibition of RNA-dependent RNA polymerase (RdRP) with a Ki value of 6.16 µM. This compound is primarily utilized in research focused on antiviral therapies against Zika virus (ZIKV). -
CYP17A1 Inhibitor
YM116 is a potent and orally active competitive inhibitor of CYP17A1, with a reported Ki of 0.38 nM. By specifically inhibiting the C17-20 lyase activity, YM116 effectively reduces the synthesis of adrenal androgens, leading to decreased serum testosterone levels and lower dehydroepiandrosterone sulfate concentrations. This compound is valuable for research applications involving androgen-related disorders and prostate health. -
CYP1B1 Degrader
PROTAC CYP1B1 degrader-2 is a VHL E3 ligase-based degrader targeting CYP1B1, exhibiting a DC50 of 1.0 nM in A549/Taxol cells after 24 hours. This compound effectively inhibits the growth, migration, and invasion of cancer cells, making it a valuable tool for research into the therapeutic potential of targeting CYP1B1 in cancer treatment. Its unique mechanism of action offers insights into the modulation of protein levels in various biological contexts. -
hCYP3A4 Inhibitor
hCYP3A4-IN-1 is a potent inhibitor of human cytochrome P450 3A4 (hCYP3A4) with notable activity in both human liver microsomes and CHO-3A4 stable cell lines, exhibiting IC50 values of 43.93 nM and 153.00 nM, respectively. This inhibitor effectively blocks CYP3A4-mediated hydroxylation of N-ethyl-1,8-naphthalimide (NEN) in a competitive manner, with a Ki of 30.00 nM. hCYP3A4-IN-1 is valuable for research applications focused on drug metabolism and interactions involving CYP3A4. -
CYP3A4 Inhibitor
Tabimorelin hemifumarate is a potent inhibitor of the cytochrome P450 enzyme CYP3A4. This compound functions as a growth hormone secretagogue, promoting the secretion of growth hormone in the body. Its key biological activities make it valuable for research applications in endocrine signaling and pharmacokinetics, particularly in studies assessing drug metabolism and interactions involving CYP3A4. -
CYP4A Hydroxylase Inhibitor
CAY 10434 is a potent inhibitor of CYP4A hydroxylase, demonstrating significant effects on vascular smooth muscle contractility. This compound enhances the contractile response to angiotensin II, achieving a maximal contractile response (Emax) of 6764 mg. CAY 10434 is valuable for research into cardiovascular physiology and the regulatory mechanisms underlying vascular reactivity. -
CYP11B2 Inhibitor
CYP11B2-IN-3 is a selective inhibitor of CYP11B2, demonstrating an IC50 value of 12.92 nM for CYP11B2 and 2341 nM for CYP11B1. This compound is orally active, making it suitable for in vivo studies. CYP11B2-IN-3 is primarily applicable in research related to hypertension, providing a valuable tool for investigating the role of CYP11B2 in adrenal steroidogenesis and blood pressure regulation. -
CYP1A2/CYP2D6/CYP3A4 Inhibitor
Peucedanol is a non-competitive inhibitor of CYP3A4 with a Ki value of 4.07 μM, while functioning as a competitive inhibitor of CYP1A2 and CYP2D6, with Ki values of 3.39 μM and 6.77 μM, respectively. This compound plays a significant role in pharmacological research by modulating drug metabolism pathways. Its ability to inhibit key cytochrome P450 enzymes makes it a valuable tool for studies examining drug interactions and metabolic regulation. -
CYP3A4 Inhibitor
Licopyranocoumarin is an isoflavonoid known for its inhibitory action on the cytochrome P450 enzyme CYP3A4, exhibiting an IC50 of 32 μM. This compound also demonstrates significant neuroprotective properties, making it a valuable reagent for studies focused on drug metabolism and neurodegenerative disorders. Researchers may utilize Licopyranocoumarin to explore its effects on enzyme activity and potential therapeutic applications in neurological research. -
CYP1B1 Inhibitor
CYP1B1-IN-1 is a selective inhibitor of cytochrome P450 1B1 (CYP1B1) with an IC50 value of 0.49 nM. This compound is valuable for studying the role of CYP1B1 in various biological processes, including the metabolism of xenobiotics and the activation of pro-carcinogens. CYP1B1-IN-1 is suitable for research applications focused on cancer biology and toxicology, providing insights into the pharmacological modulation of CYP1B1 activity.
